Literature DB >> 10082371

Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease.

S W Rick1, I A Topol, J W Erickson, S K Burt.   

Abstract

The changes in the inhibitor binding constants due to the mutation of isoleucine to valine at position 84 of HIV-1 protease are calculated using molecular dynamics simulations. The calculations are done for three potent inhibitors--KNI-272, L-735,524 (indinavir or MK-639), and Ro 31-8959 (saquinavir). The calculations agree with the experimental data both in terms of an overall trend and in the magnitude of the resulting free energy change. HIV-1 protease is a homodimer, so each mutation causes two changes in the enzyme. The decrease in the binding free energy from each mutated side chain differs among the three inhibitors and correlates well with the size of the cavities induced in the protein interior near the mutated residue. The cavities are created as a result of a mutation to a smaller side chain, but the cavities are less than would be predicted from the wild-type structures, indicating that there is significant relaxation to partially fill the cavities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10082371      PMCID: PMC2144074          DOI: 10.1002/pro.5560070809

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  24 in total

1.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

Authors:  S V Gulnik; L I Suvorov; B Liu; B Yu; B Anderson; H Mitsuya; J W Erickson
Journal:  Biochemistry       Date:  1995-07-25       Impact factor: 3.162

Review 2.  Structural and genetic analysis of protein stability.

Authors:  B W Matthews
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

Review 3.  Structure-based inhibitors of HIV-1 protease.

Authors:  A Wlodawer; J W Erickson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

4.  Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.

Authors:  Y X Wang; D I Freedberg; T Yamazaki; P T Wingfield; S J Stahl; J D Kaufman; Y Kiso; D A Torchia
Journal:  Biochemistry       Date:  1996-08-06       Impact factor: 3.162

5.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

Authors:  S A Danner; A Carr; J M Leonard; L M Lehman; F Gudiol; J Gonzales; A Raventos; R Rubio; E Bouza; V Pintado
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

7.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

8.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.

Authors:  Z Chen; Y Li; E Chen; D L Hall; P L Darke; C Culberson; J A Shafer; L C Kuo
Journal:  J Biol Chem       Date:  1994-10-21       Impact factor: 5.157

9.  Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.

Authors:  E T Baldwin; T N Bhat; S Gulnik; B Liu; I A Topol; Y Kiso; T Mimoto; H Mitsuya; J W Erickson
Journal:  Structure       Date:  1995-06-15       Impact factor: 5.006

10.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.

Authors:  J A Partaledis; K Yamaguchi; M Tisdale; E E Blair; C Falcione; B Maschera; R E Myers; S Pazhanisamy; O Futer; A B Cullinan
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  3 in total

1.  Conformational selection and adaptation to ligand binding in T4 lysozyme cavity mutants.

Authors:  Carlos J López; Zhongyu Yang; Christian Altenbach; Wayne L Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

2.  Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

Authors:  Xiaoqing Liu; Zhilong Xiu; Ce Hao
Journal:  J Comput Aided Mol Des       Date:  2009-02-15       Impact factor: 3.686

3.  Accurate Prediction of Inhibitor Binding to HIV-1 Protease Using CANDOCK.

Authors:  Zackary Falls; Jonathan Fine; Gaurav Chopra; Ram Samudrala
Journal:  Front Chem       Date:  2022-01-17       Impact factor: 5.221

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.